Topic hub

How doctors decide what to prescribe

What weighs on a prescribing decision when a patient is ready to start something new: cost, coverage, safety, familiarity, and what the patient walked in asking for.

11 insights·0 studies

What did the panels say about how doctors decide what to prescribe?

  1. #

    65.2%

    65.2% rate a 20-minute meeting with a medical science liaison at least moderately useful to their practice, against 17.7% for a 20-minute meeting with a sales representative about the same kind of medicine — Medical science liaisons: 60.1% of US physicians and other prescribers want real-world and subgroup evidence for patients like theirs, and 65.2% rate a liaison meeting useful against 17.7% for a sales rep

    base 198

  2. #

    37.1%

    37.1% (26 of 70) would still prescribe the brand-name medicine they prefer when it costs the patient $150 a month against $5 for an older generic, down from 95.7% (67 of 70) at $25 and 55.7% (39 of 70) at $75; none of the 70 moves back to the brand as the price rises. — Patient out-of-pocket cost and prescribing: US physicians keep a preferred brand at $25 a month, split at $75, and 62.9% switch to a generic at $150

    base 70

  3. #

    22.9%

    22.9% (16 of 70) are likely, a 6 or 7 of 7, to prescribe a new medicine with a clear phase 3 benefit in the next three months when most plans do not cover it and a patient pays about $250 a month, against 72.9% (51 of 70) when it is covered with no prior authorization and a $30 copay, and 54.3% (38 of 70) when prior authorization takes one to two weeks. — New medicine launches: 72.9% of US physicians and other prescribers would try one in its first months when it is covered, 22.9% when patients pay $250 a month

    base 70

  4. #

    66.7%

    Asked by a rep for a medicine they already prescribe for a 10-minute in-person visit, 66.2% of US clinicians would agree to one every three months, 58.1% to one a month and 31.8% to one every two weeks; the share who would decline rises from 30.8% to 39.4% to 66.7%. — Pharma rep visits: 66.7% of US clinicians, mostly dermatologists, would turn away a rep who asks to come every two weeks, against 39.4% for a monthly visit

    base 198

  5. #

    88.9%

    For a healthy 35-year-old with moderate-to-severe eczema who dislikes injections and asks for a pill, 88.9% of US dermatologists would start an oral JAK inhibitor rather than an injectable biologic when both cost the patient $0 a month; 81.7% still would when the JAK costs $30 a month more, 69.0% at $75 more and 46.8% at $150 more. — Oral JAK inhibitor or biologic: 88.9% of US dermatologists start a pill-seeking eczema patient on the JAK, and only a $150 a month gap tips most to the biologic

    base 126

What has Brox published on how doctors decide what to prescribe?Newest first

What do people ask about how doctors decide what to prescribe?

What do physicians want from a medical science liaison that a sales rep cannot give them?
Real-world and subgroup evidence for patients like their own: 60.1% of US physicians and other prescribers on the Brox HCP panel name it as what they most want from a medical science liaison that a sales rep cannot give, and 65.2% rate a 20-minute liaison meeting at least moderately useful against 17.7% for a rep meeting (n=198, November 2026).Read the insight
How much does a patient's out-of-pocket cost change what a physician is willing to prescribe?
Between $25 and $75 a month: 4.3% of US physicians and other prescribers outside dermatology would pick a $5 generic over the brand-name medicine they prefer when the brand costs the patient $25 a month, 44.3% at $75 and 62.9% at $150 (n=70, November 2026).Read the insight
What makes a physician try a newly launched medicine in its first six months: the trial data, a peer, the rep, or coverage?
Coverage, more than trial data, decides it in practice: 72.9% of US prescribers outside dermatology are likely to prescribe a newly launched medicine with a clear phase 3 benefit in its first months when it is covered without prior authorization, 54.3% when prior authorization is needed and 22.9% when a patient pays $250 a month, even though 55.7% name trial data as their single biggest trigger (n=70, November 2026).Read the insight
What makes a doctor stop seeing pharma reps altogether?
Being asked too often, and their employer: 66.7% of US clinicians on the Brox HCP panel would decline a 10-minute pharma rep visit every two weeks against 39.4% monthly, and 24 of the 36 who no longer see reps name a practice or health system restriction (n=198, November 2026).Read the insight
What makes a dermatologist choose a JAK inhibitor over a biologic, and what makes them avoid it?
88.9% of US dermatologists on the Brox panel would start a healthy 35-year-old with moderate-to-severe eczema who asks for a pill on an oral JAK inhibitor rather than an injectable biologic when both cost the patient $0 a month, falling to 81.7% at a $30 monthly gap, 69.0% at $75 and 46.8% at $150 (n=126, November 2026).Read the insight
How do clinicians want to hear about a new indication for a medicine they already prescribe, and which channel actually changes what they prescribe?
When a medicine they already prescribe gains a new FDA-approved indication, 73.2% of US clinicians on the Brox panel would ignore the manufacturer's email about it first, and 71.7% would rather hear first from a colleague, a conference, or a journal (n=198, October 2026).Read the insight
How do physicians decide between a generic and a branded medicine when both are on formulary?
When a patient asks for the brand and their plan covers both versions, 88.9% of US clinicians on the Brox panel would prescribe the generic once the brand costs the patient $15 a month more (n=198, October 2026).Read the insight
How do specialists decide which of several similar biologics to start a new patient on?
When two psoriasis biologics have similar efficacy and safety, 90.6% of US dermatologists say the insurance plan's preference decides which one they start (n=117, October 2026), and 86.3% are very likely to switch to the plan-preferred biologic when their own choice would cost the patient just $25 a month more.Read the insight
What makes an oncologist adopt a newly approved first-line cancer therapy straight away, rather than wait for guidelines, payer coverage or peers?
14 of 18 US oncologists in the Brox HCP panel say prior authorization or coverage denials, not the trial data or the guideline listing, are what most often delay their first prescription of a newly approved first-line cancer regimen (n=18, October 2026).Read the insight
When an adult patient has ADHD alongside significant anxiety, what does a US physician do first, and what would change it?
Of the ten US physicians on the panel who manage adult ADHD with comorbid anxiety, none refers the patient straight out: six treat the anxiety first, and nine said evidence that one daily medicine improved both conditions would make them treat the ADHD themselves (September 2026).Read the insight

Other topics

How should you read these findings?

Where the numbers come from. Every figure on this site is a predicted response from Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The base under each figure is the number of clones behind it.

Where the real data comes from. The long-form video interviews with the real people the clones are built from. A quote is always shown with the interview line it was predicted from.

What you can take away. Insights publish their tabulation as CSV and JSON: question, option, count, percentage and base. Never per-person rows.

Ask this of your own customers: humans@brox.ai